Skip to content
Spiritual Quotes – Lifestyle
Author:
Annexon Biosciences
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy – Highlighting Key Aspects of Phase 3 ARCHER II Trial
October 28, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
September 24, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2026
Annexon to Participate in Upcoming September Investor Conferences
September 2, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
August 12, 2026
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
August 6, 2026
1
2
Next Page
→